Mersana Therapeutics

Search
  • About
    • Mission & Vision
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
    • ESG
      • Our Responsibility
      • Who We Are
      • Our Organization
      • Patient Access and Clinical Trial Practices
      • Our Community
      • Our Planet
    • Partnering
  • Platforms
    • About ADCs
    • DolaLock Technology
    • Dolaflexin
    • Dolasynthen
    • Immunosynthen
  • Pipeline
    • Overview
    • Upifitamab Rilsodotin
    • XMT-1660
    • XMT-2056
  • Publications
  • Investors & Media
    • Overview
    • Stock
    • Analysts
    • SEC Filings
    • News
    • Events
    • Annual Meeting
    • Governance
    • Quarterly Results
    • Contact Us
  • People
    • Culture
    • Benefits
    • Careers
  • Contact
Immunosynthen, Publications, XMT-2056

XMT-2056, a HER2-Directed STING Agonist Antibody-Drug Conjugate, Exhibits ADCC Function that Synergizes with STING Pathway Activation and Contributes to Anti-tumor Responses

Immunosynthen, Publications, XMT-2056

XMT-2056: A Her-2 Targeted Immunosynthen STING agonist antibody drug conjugate

August, 2022

Immunosynthen, Publications, XMT-2056

XMT-2056: A Her-2 Targeted Immunosynthen STING agonist antibody drug conjugate

August, 2022

Immunosynthen, Publications, XMT-2056

XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab

April, 2022

Immunosynthen, Program, Publications

Tumor cell-targeted STING-agonist antibody-drug conjugates achieve potential anti-tumor activity by delivering STING agonist specifically to tumor cells and FcγRI-expressing subset of myeloid cells

April, 2022

Immunosynthen, Publications

STING-Agonist ADCs Targeting Tumor-Associated Antigens Coordinate Immune-Mediated Killing of Antigen-Negative Cancer Cells

Immunosynthen, Publications, XMT-2056

XMT-2056: Tumor-targeted Innate Immune Activation via a STING-agonist Antibody Drug Conjugate

October, 2021

Immunosynthen, Platform, Program, Publications, XMT-2056

XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity

April, 2021

Immunosynthen, Platform, Program, Publications, XMT-2056

Tumor cell-intrinsic STING pathway activation leads to robust induction of Type III Interferons and contributes to the anti-tumor activity elicited by STING agonism

April, 2021

Immunosynthen, Publications

Immunosynthen: STING-Agonist ADC Platform

November 2020

© 2023 Mersana Therapeutics, All Rights Reserved. Privacy Policy | Terms of Use
linkedin icon twitter icon
logo
  • About
    • Mission & Vision
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
    • ESG
      • Our Responsibility
      • Who We Are
      • Our Organization
      • Patient Access and Clinical Trial Practices
      • Our Community
      • Our Planet
    • Partnering
  • Platforms
    • About ADCs
    • DolaLock Technology
    • Dolaflexin
    • Dolasynthen
    • Immunosynthen
  • Pipeline
    • Overview
    • Upifitamab Rilsodotin
    • XMT-1660
    • XMT-2056
  • Publications
  • Investors & Media
    • Overview
    • Stock
    • Analysts
    • SEC Filings
    • News
    • Events
    • Annual Meeting
    • Governance
    • Quarterly Results
    • Contact Us
  • People
    • Culture
    • Benefits
    • Careers
  • Contact